ClinicalTrials.gov (NCT00942188) A Study of LY2189102 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 532275
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.